Physician profile
David M Johnson
NPI 1831154343
$5,431.82
in general payments reported to CMS, 2019-2025
25 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $980 · 2021: $1,017 · 2022: $824 · 2023: $570 · 2024: $367 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,038.13 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,003.64 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $709.15 | 2019-2023 | |
| Glaxosmithkline, LLC. | $706.51 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $604.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $564.72 | 2019-2025 | Farxiga, Breztri |
| Mylan Specialty L.P. | $128.91 | 2021-2023 | Yupelri |
| Lilly USA, LLC | $79.87 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.08 | 2021-2023 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $71.68 | 2021 | |
| Medtronic, INC. | $68.90 | 2023-2025 | Inceptiv, Intellis Adaptivestim, Minimed 780g |
| Sequel Med Tech, LLC | $65.76 | 2025 | Twiist |
| E.R. Squibb & Sons, L.L.C. | $63.50 | 2019-2021 | |
| Abbott Laboratories | $50.27 | 2021-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $40.75 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.51 | 2022 | |
| Abbvie INC. | $32.16 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.84 | 2019 | |
| Dexcom, INC. | $16.53 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $15.28 | 2021 | |
| Eisai INC. | $11.66 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.23 | 2025 | Voquezna |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.